One meta-analysis of observational studies involving 338 KTRs supports the effectiveness of GLP-1 RAs, demonstrating benefits in glycemic control, reductions in proteinuria, and weight loss, without significant interference with tacrolimus blood levels [22]
J Cell Biochem (2013) 114(4):84453
The durability of tirzepatide's effect reflects its mechanism as a true metabolic modifier, not just an appetite suppressant, with benefits extending beyond the scale to improved blood sugar control, reduced inflammation, and enhanced cardiovascular health markers
doi: 10.15407/ubj93.01.018 190 MehtaP.McAuleyD
Not just another search for Weight Loss Reno
The post says access decisions center on disease state and risk profile rather than weight status, so a type 2 diabetes diagnosis, cardiovascular risk factors, or metabolic markers can support therapy at a normal BMI